-
Mashup Score: 0
The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial. @sitcancer #SITC21 https://t.co/jzqhEFdWUu
-
-
Mashup Score: 1Safety and preliminary evidence for efficacy for propranolol + pembrolizumab in metastatic melanoma - 2 year(s) ago
Marc S. Ernstoff, MD, National Institutes of Health, Bethesda, MD, gives us an update on the results of a Phase…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marc Ernstoff of @NIH discusses the safety and preliminary evidence for efficacy for propranolol plus pembrolizumab in metastatic #melanoma Watch: 👉https://t.co/LKXg7LxqzQ👈 @sitcancer #SITC21 #ImmunoOnc #Skin Cancer
-
-
Mashup Score: 0Areas of unmet need for patients with melanoma - 2 year(s) ago
Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on key areas of melanoma…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allison Betof Warner (@DrBetofMDPhD) of @sloan_kettering discusses areas of unmet need for patients with #melanoma Watch: 👉https://t.co/P5vouYFC9v👈 @sitcancer #SITC21 #ImmunoOnc
-
-
Mashup Score: 1
Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the benefits and risks…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allison Betof Warner (@DrBetofMDPhD) of @sloan_kettering discusses the benefits and risks of reinduction ipilimumab/nivolumab in patients with #melanoma Watch: 👉https://t.co/a8EDceiZjT👈 @sitcancer #SITC21 #ImmunoOnc"
-
-
Mashup Score: 0SITC clinical practice guidelines on immune checkpoint inhibitor-related adverse events - 2 year(s) ago
Whilst immune checkpoint inhibitors (ICIs) have considerably improved patient outcomes in several clinical settings, they are associated with a range…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marc Ernstoff of @NIH discusses the SITC clinical practice guidelines on immune checkpoint inhibitor-related adverse events Watch: 👉https://t.co/M3EGFVIFsV👈 @sitcancer #SITC21 #ImmunoOnc
-
-
Mashup Score: 5Jeffrey Weber on Coronavirus, Cancer, and Immunotherapy Navigating Clinical Trials and Treatment - The ASCO Post - 2 year(s) ago
SITC 2021 Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline in trial enrollment has…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment https://t.co/N7siHDeJSy #sitc21 #immunotherapy #cancer #coronavirus #clinicaltrials @nyulangone https://t.co/ShullmFA5c
-
-
Mashup Score: 0The rise of virtual clinical trials - 2 year(s) ago
Kannan Natarajan, PhD, Pfizer, Brooklyn, NY, comments on the rapid growth of virtual clinical trials during the COVID-19 pandemic and…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Kannan Natarajan of @pfizer talks on the rise of virtual clinical trials Watch: 👉https://t.co/ziUSYsxoQA👈 @sitcancer @PfizerCongress #SITC21 #ImmunoOnc
-
-
Mashup Score: 0Recent drug approvals for NSCLC - 2 year(s) ago
Eric K. Singhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of recent drug…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Eric Singhi (@esinghimd) of @MDAndersonNews discusses recent drug approvals for #NSCLC Watch: 👉https://t.co/XtIIbFyfmS👈 @sitcancer #SITC21 #ImmunoOnc
-
-
Mashup Score: 0Yevgeniy Semenov on Cutaneous Immune-Related Adverse Events and Response to Immune Checkpoint Inhibitors - The ASCO Post - 2 year(s) ago
SITC 2021 Yevgeniy R. Semenov, MD, of Massachusetts General Hospital and Harvard Medical School, discusses new findings suggesting cutaneous adverse events such as vitiligo, lichenoid dermatitis, and psoriasis—which often occur in patients with cancer who receive immune checkpoint inhibitors—may be strongly associated with response to…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yevgeniy R. Semenov, MD, on Cutaneous Immune-Related Adverse Events and Response to Immune Checkpoint Inhibitors https://t.co/rwerclt23m #SITC21 #immunotherapy @EugeneSemenovMD @MGHMedicine @MGHCancerCenter @Massgeneralnews Also see @JAMADerm report: https://t.co/OmL3R18tfI https://t.co/H5NSLd9nu8
-
Alpha DaRT was designed to permit highly potent and conformal alpha-irradiation of solid tumors through the intratumoral delivery of radium-224 impregnated sources @sitcancer #SITC21 https://t.co/S43un8zqWl https://t.co/5JAUOA401K